A clinical trial of DS-8201a in HER2 positive(HER2≥1) metastatic/recurrent uterine carcinosarcoma patients (NCCH1615,STATICE trial)
Phase of Trial: Phase II
Latest Information Update: 15 Apr 2018
At a glance
- Drugs Trastuzumab-deruxtecan (Primary)
- Indications Uterine cancer
- Focus Therapeutic Use
- Acronyms STATICE
- 09 Jan 2018 Status changed from not yet recruiting to recruiting.
- 12 Dec 2017 Planned initiation date changed from 1 Dec 2017 to 19 Dec 2017.
- 13 Oct 2017 New trial record